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Abstract: 
Background: Maternal gestational diabetes mellitus (GDM) has been associated 
with adverse outcomes in the offspring. Growing evidence suggests that the 
epigenome may play a role, but most previous studies have been small and 
adjusted for few covariates. The current study meta-analyzed the association 
between maternal GDM and cord blood DNA methylation in the Pregnancy and 
Childhood Epigenetics Consortium. 
Methods: Seven pregnancy cohorts (3,677 mother-newborn pairs, 317 with 
GDM) contributed results from epigenome wide association studies, using DNA 
methylation data acquired by the Infinium HumanMethylation450 array. 
Associations between GDM and DNA methylation were examined using robust 
linear regression, adjusting for potential confounders. Fixed-effects meta-
analyses were performed using METAL. Differentially methylated regions 
(DMRs) were identified by taking the intersection of results obtained using two 
regional approaches: comb-p and DMRcate. 
Results: Two DMRs were identified by both comb-p and DMRcate. Both regions 
were hypomethylated in newborns exposed to GDM in utero, compared with 
controls. One DMR (chr1:248100345-248100614) was located in the OR2L13 
promoter and the other (chr10:135341870-135342620) was located in the gene 
body of CYP2E1. Individual CpG analyses did not reveal any differentially 
methylated loci based on a PFDR threshold of 0.05. 
Conclusions: Maternal GDM was associated with lower cord blood methylation 
levels within two regions, including the promoter of OR2L13, a gene associated 
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with autism spectrum disorder, and the gene body of CYP2E1, which is 
upregulated in type 1 and type 2 diabetes. Future studies are needed to 
understand whether these associations are causal and possible health 
consequences. 
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Background: 
Gestational diabetes mellitus (GDM) is one of the most common 
pregnancy complications, with prevalence estimates ranging from 2% to 25% 
depending on the screening and diagnostic criteria used and the population 
examined (1, 2). In addition to the adverse pregnancy and delivery outcomes 
associated with GDM, which can include preeclampsia, macrosomia, and 
shoulder dystocia (3), women diagnosed with GDM are four times more likely to 
have children who develop metabolic syndrome later in life and twice as likely to 
have children who become overweight or obese (4). There is also evidence that 
maternal GDM during pregnancy alters fetal growth trajectories (5) and adversely 
affects neurodevelopment (6, 7). Thus, understanding the molecular changes 
related to prenatal exposure to GDM could have widespread implications for 
children’s health. 
One potential mechanism underlying such a diverse array of GDM-
associated outcomes is epigenetic dysregulation. In support of this, a growing 
number of studies have observed associations between GDM and cord blood 
DNA methylation patterns (8-17). However, the majority of studies have been 
small (e.g., fewer than 100 participants or fewer than 30 GDM cases), adjusted 
for few if any covariates, and used lenient or no adjustment for multiple testing 
(8-10, 12-15, 17), which may have contributed to a lack of replication of results 
across studies. 
There has therefore been a call for research on GDM and offspring DNA 
methylation within larger studies (18). The current study conducted a meta-
  8 
analysis of results from epigenome-wide association studies (EWAS) of GDM 
and cord blood DNA methylation patterns from seven cohorts participating in the 
Pregnancy and Childhood Epigenetics (PACE) consortium (19). Additionally, we 
conducted a look-up in our meta-analysis results for CpGs that were previously 
identified as differentially methylated in prior publications. 
 
Methods: 
 
Participating Cohorts: 
All cohorts in the PACE consortium (19) were invited to participate in the 
current meta-analysis. Seven cohorts, representing eight countries, participated, 
contributing a total of 317 GDM cases and 3,360 controls (Table 1, Table S1). 
These cohorts are the Avon Longitudinal Study of Parents and Children 
(ALSPAC), the Genome-Wide Population-Based Association Study of Extremely 
Overweight Young Adults (GOYA), the Healthy Start study, the Proyecto Infancia 
y Medio Ambiente (INMA) study, the Prediction and Prevention of Preeclampsia 
and Intrauterine Growth Restriction (PREDO) study, Project Viva, and a pooled 
analysis of three cohorts: the Rhea study (RHEA), The ENVIRonmental influence 
ON early AGEing in early life (ENVIRONAGE) study, and the Piccolipiù study  
(RHEA/ENVIRONAGE/Piccolipiù). Cohort details are described in the “Cohort-
Specific Information” section of Supplementary Data. Each cohort received 
ethics approval and informed consent from participants prior to data collection, 
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and the current meta-analysis was approved by the Health Sciences Institutional 
Review Board of the University of Southern California.  
 
Gestational Diabetes: 
Participants diagnosed with type 1 or type 2 diabetes prior to the index 
pregnancy were excluded from analyses. The criteria used to classify GDM 
cases are summarized by cohort in Table 1 and are also described in more detail 
in the Supplementary Data. All cohorts except Piccolipiù used information 
abstracted from medical records as their primary method for identifying GDM 
cases. Due to a lack of international consensus, the criteria used to classify GDM 
differ by country and have changed over time. In the United States and some 
European countries, GDM is often diagnosed using a 2-step approach, which 
entails universal screening with a 50-g glucose challenge test, followed by a 100-
g 3-hour oral glucose tolerance test (OGTT) for those who test positive (20). In 
contrast, some European countries have adopted the International Associations 
of the Diabetes and Pregnancy Study Groups (IADPSG) guidelines (21), which 
recommend a 1-step approach, in which a 75-g 2-hour OGTT is performed for all 
women at 24-28 weeks’ gestation. Furthermore, some countries use a selective 
approach and only administer GDM diagnostic tests to women with traditional 
risk factors. GDM cases from Healthy Start, Project Viva, Rhea, and 
ENVIRONAGE were classified based on the 2-step approach, using the 
Carpenter-Coustan criteria (22). GDM cases from PREDO were classified based 
on the IADPSG 1-step approach. Piccolipiù identified GDM cases based on self-
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reported questionnaire data collected at delivery, and all but one case was 
confirmed using medical record data (IADPSG 1-step approach (21)). GDM 
cases from INMA were diagnosed using a selective screening approach, where 
women at high risk for GDM were administered a glucose challenge test, 
followed by a diagnostic OGTT, using the Carpenter-Coustan criteria (22). GDM 
cases from ALSPAC and GOYA were diagnosed based on the practices at the 
time in the United Kingdom and Denmark, respectively, in which diagnostic tests 
were only performed for women 1) at high risk for GDM based on established risk 
factors or 2) with glycosuria (23, 24). Given anticipated under-reporting of GDM 
in the medical records, information from telephone interviews was also used to 
classify GDM cases in GOYA. 
 
Methylation Measurements: 
Cord blood DNA was bisulfite-converted using the EZ-96 DNA Methylation 
Kit (Zymo Research Corporation, Irvine, USA). Each cohort measured DNA 
methylation using the Infinium® HumanMethlyation450k BeadChip array 
(Illumina Inc., San Diego, United States), either at Illumina or in cohort-specific 
laboratories, and completed its own quality control and normalization of data, as 
described in the Supplementary Data. Since the PACE consortium has observed 
that extreme outliers (> 3 times the interquartile range) can have a large impact 
on results, they were removed prior to analyses. For all analyses, normalized, 
untransformed betas were evaluated as the outcomes. 
 
  11 
Cohort-Specific Statistical Analyses: 
Cohorts ran independent EWAS models according to the same analysis 
plan, using robust linear regression, as this method controls for possible 
heteroscedasticity and potential outliers. Only singleton pregnancies were 
included in analyses. GDM was modeled as the exposure of interest and the cord 
blood DNA methylation level at each CpG was modeled as the outcome. 
Regression models were adjusted for hypothesized confounders, which included 
newborn’s sex, maternal age, maternal education level, maternal body mass 
index (pre-pregnancy or early pregnancy), maternal smoking status during 
pregnancy (ever versus never), and maternal genetic ancestry (if available) or 
maternal race/ethnicity. Cohort-specific details for covariate assessment are 
described in the Supplementary Data. First, we adjusted only for this baseline set 
of covariates (results are presented in the Supplementary Data), such that results 
could be compared with previous studies, which have generally not accounted for 
cord blood cell heterogeneity. However, our final model was additionally adjusted 
for cord blood cell fractions, including B cells, CD8+ T cells, CD4+ T cells, 
granulocytes, natural killer cells, monocytes, and nucleated red blood cells, which 
were estimated using a cord blood reference panel (25). We also examined 
results from two of the larger participating cohorts (PREDO and Project Viva) 
after additional adjustment for parity. Since results were very similar (Tables S2-
S3), parity was not included in the final model. 
 
Meta-Analyses: 
  12 
METAL (26) was used to conduct inverse variance-weighted fixed effects 
meta-analyses, using results from the cohort-specific analyses. Control probes, 
probes mapping to the X and Y chromosomes, and probes that have been shown 
to cross-hybridize or which target polymorphic CpGs or contain SNPs at the 
single base pair extension (27) were excluded. A total of 380,878 CpGs were 
therefore included in the meta-analyses. Probes were annotated to hg19 using 
the IlluminaHumanMethylation450kanno.ilmn12.hg19 R package (28). After 
meta-analyses were complete, a second analyst ran shadow meta-analyses to 
rule out potential human error. CpGs were considered differentially methylated if 
the false discovery rate-adjusted p-value (PFDR) was < 0.05.  
Potential heterogeneity between studies was assessed using Cochran’s Q 
statistic and I2. Additionally, leave-one-out meta-analyses (i.e., comparison of 
results after the sequential removal of one cohort and a meta-analysis of the 
remaining six cohorts) were conducted to evaluate the influence of each 
individual cohort on the results. 
Differentially methylated regions (DMRs) were identified from meta-
analysis results by taking the intersection of DMRs identified using two different 
software programs: comb-p (29) and DMRcate (30). Comb-p identifies regions 
enriched for low p-values, uses the Stouffer-Liptak method to correct for auto-
correlation, and adjusts for multiple testing using the Sidak correction (29). 
DMRcate calculates two smoothed estimates for each chromosome (one 
weighted by F-statistics, one not) and uses a Sattherwaite approximation to 
compare these estimates; it then adjusts for multiple testing using the FDR 
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method (30). These approaches were selected, because they can be applied to 
meta-analysis results. Windows of 500 and 1,000 base pairs were compared for 
each approach. For comb-p, a p-value threshold of 1x10-3 was used to specify 
the start of each region, and a distance of 200 base pairs was selected for 
extending the region. For DMRcate, the default settings were used, as 
recommended (30), and FDR thresholds of 0.05 and 0.01 were compared. 
 
Sensitivity Analyses 
Since the seven participating cohorts represent different geographic 
regions and differ in the timing of participant recruitment and the criteria used to 
classify GDM cases, we ran a series of sensitivity meta-analyses. We compared 
meta-analysis results after restricting to 1) cohorts with GDM cases identified by 
selective versus universal screening, 2) cohorts with GDM cases identified using 
a 1-step 75 g versus a 2-step 100 g OGTT, 3) European versus U.S. cohorts, 
and 4) cohorts that recruited participants prior to 2004 versus after 2004. 
 
Look-Up Analyses: 
In an effort to replicate previous findings, a look-up of CpGs previously 
identified as differentially methylated by GDM status was conducted within 
results from the meta-analyses (both with and without adjustment for estimated 
cell proportions). Relevant studies were identified in PubMed using the following 
search terms: Gestational diabetes AND DNA methylation. We focused on 
studies that: 1) were not included in the current meta-analyses, 2) included > 10 
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GDM cases, 3) measured DNA methylation in cord blood using Illumina’s 450k, 
EPIC, or 27k array, 4) adjusted for multiple testing using any method, and 5) 
provided effect estimates and p-values for individual CpGs. Two studies met 
these criteria (9, 12). These studies collectively reported a total of 110 
differentially methylated CpGs, none of which were common. Additionally, nine 
CpGs within two genes (MEST, NR3C1) that were identified as differentially 
methylated by GDM status in both cord blood and placenta in a previous 
candidate gene study (11), which are represented on the 450k array, were 
evaluated. Of these 119 CpGs, 32 were cross-reactive or polymorphic, or the 
CpG probe contained a SNP at the single base pair extension (27). These 32 
CpGs were therefore excluded, leaving a total of 87 CpGs for the look-up 
analyses. 
 
Results: 
 
Study Characteristics: 
Characteristics of participating studies are shown in Table 1 and Table S1. 
The number (%) of GDM cases per study ranged from 12 (7.7%) for INMA to 180 
(23.1%) for PREDO. The majority of participants were of European ancestry, and 
about half of the newborns were male (N = 1,900, 51.7%). 
 
Meta-Analyses for the Individual CpG Results 
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Probe numbers and the level of inflation () for individual cohort results 
are shown in Table S4. The  for the meta-analyses was 1.15. Meta-analysis 
results are summarized in a Manhattan plot (Figure 1). No CpGs were identified 
as differentially methylated by GDM status based on a PFDR < 0.05, but six were 
identified based on a PFDR < 0.10 (Table 2). While the directions of effect were 
generally consistent for Healthy Start; INMA; PREDO; Project Viva; and the 
pooled analysis of Rhea, Environage, and Piccolipiù; they often differed for 
ALSPAC or GOYA (Table 2). For five of the CpGs, there was not strong evidence 
of heterogeneity (I2 < 10.0, Pheterogeneity > 0.36), but for one CpG (cg11723077), 
there was evidence of moderate heterogeneity (I2=38.7, P=0.13). However, effect 
estimates were similar across the leave-one-out meta-analyses (results shown in 
Figure S1 and Table S5).  
 
Look-Up Analysis Results 
The full look-up analysis results are presented in Tables S6 and S7 within 
the Supplementary Data. Of the 87 CpGs examined, four were differentially 
methylated (uncorrected P < 0.05) in the same direction in the meta-analysis that 
accounted for cell heterogeneity (Table S7). These four CpGs (cg01203331, 
cg03345925, cg08471713, cg20507276) were annotated to a total of seven 
genes: NOP56, SNORD56, SNORD57, SNORD86; ZC3H3; MEOX1; and 
OR2L13, respectively. However, based on the 87 tests conducted, FDR-
corrected p-values exceeded 0.05 for all of the CpGs evaluated. 
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DMRs Identified from the Meta-Analysis Results 
Using individual CpG results from the meta-analyses, comb-p identified five 
regions that were differentially methylated by GDM status (Table S8). Comb-p 
results were the same when either a 500 or 1,000 base pair window was used. 
DMRcate identified two DMRs when using an FDR threshold of 0.10. One DMR 
was identified when using the 500 base pair window (chr1:248100407-
248100614) and the other when using the 1,000 base pair window 
(chr10:135341870-135342620) (Table S9). Both of these DMRs overlapped two 
DMRs that had also been identified by comb-p (Table 3). One was located in the 
promoter region of OR2L13 and was also annotated to pseudogene CLK3P2. 
The second overlapped a CpG island in the gene body of CYP2E1. %Methylation 
levels in both regions were lower in the GDM case, compared with control, group, 
and effect estimates were generally consistent for the individual CpGs contained 
within each region (Figure S2). DMRcate did not identify any DMRs when using 
an FDR threshold of 0.05. 
 
Sensitivity Analysis Results 
Results were generally similar for the six CpGs with a PFDR < 0.10, and 
also for CpGs within the 2 DMRs identified by comb-p and DMRcate, when 
restricting to cohorts with GDM cases identified by a 1-step 75 g OGTT versus a 
2-step 100 g OGTT or using selective versus universal screening. They were 
also generally similar for U.S. versus European cohorts and for cohorts that 
recruited participants prior to versus after 2004 (Figures S3-S5). 
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Discussion: 
While previous studies have investigated associations between maternal 
GDM and newborn DNA methylation (8-16), the majority have been small, used 
lenient or no adjustment for multiple testing, did not consider regional methylation 
differences, and adjusted for a limited number of covariates. In particular, few 
studies have adjusted for cell heterogeneity, an important source of variability in 
DNA methylation (31). Results have been inconsistent between these previous 
studies, raising questions of robustness and reproducibility. The current study 
therefore conducted meta-analyses of EWAS results from seven cohorts (3,677 
mother-newborn pairs, 317 with GDM) participating in the PACE consortium (19), 
which examined associations between GDM and cord blood DNA methylation, 
after adjusting for a larger number of potential confounders. We evaluated 
methylation differences at both the regional and individual CpG level. 
Using two dimension reduction approaches (comb-p (29) and DMRcate 
(30)), we identified two regions that are differentially methylated by GDM status. 
One of the DMRs identified by the meta-analysis (chr1:248100276-248100614) is 
located in the promoter region of OR2L13, a gene which codes for an olfactory 
receptor (9). Methylation levels in this region were lower in cord blood from GDM 
exposed, compared with unexposed, newborns. This finding is consistent with a 
previous study by Quilter et al., which observed lower cord blood methylation 
levels at a CpG located in this DMR (cg20507276) among GDM exposed 
newborns (9). This same CpG has also been identified as differentially 
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methylated in both blood and buccal cells from autism spectrum disorder (ASD) 
cases versus controls (32). While the mechanism by which OR2L13 may 
contribute to ASD is currently unknown, olfactory dysfunction has been 
associated with more severe social impairments among individuals with ASD 
(32). Since children exposed to maternal GDM in utero have a higher risk of 
developing ASD (6), future investigation into the potential mediating role of 
OR2L13 in GDM-associated ASD is merited. Methylation levels in the second 
DMR (chr10:135341933-135342560) were also lower in the GDM case, 
compared with control, group. This DMR is located in a CpG island within the 
gene body of CYP2E1, which codes for an enzyme that is highly expressed in 
the liver and metabolizes ethanol, numerous drugs, and certain protoxicants (33). 
Although, to our knowledge, the CpGs within this DMR have not previously been 
associated with in utero exposure to GDM, increased CYP2E expression has 
been observed in peripheral blood from individuals with type 1 and type 2 
diabetes (33). 
In contrast with the DMR results, we did not identify any individual 
differentially methylated CpGs when using a conservative PFDR threshold of 0.05. 
When using a more lenient PFDR threshold of 0.10, six individual CpGs 
(cg00812770, cg11723077, cg22791932, cg17588003, cg11187204, 
cg10139436) were identified as differentially methylated by GDM status, none of 
which had been identified in the previous studies that we reviewed. Three of 
these CpGs (cg11723077, cg22791932, and cg17588003) were annotated to 
genes: SYNJ2, ZFPM1, and C17orf87, respectively, and a fourth CpG 
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(cg00812770) was located in a long intergenic non-coding RNA (LINC01342). 
The remaining two CpGs were not annotated to any genes, and the potential 
consequences of altered methylation at these loci are currently unclear.  
The 13 CpGs comprising the two DMRs identified by both comb-p and 
DMRcate were not identified as differentially methylated in individual CpG meta-
analyses, likely due to the greater statistical power of the DMR approaches. 
Additionally, the six CpGs identified as differentially methylated based on a PFDR 
< 0.10 in the individual CpG analyses were not identified by either comb-p or 
DMRcate. It is possible that these six CpGs are false positives, since they did not 
reach statistical significance after applying a more conservative threshold of PFDR 
< 0.05. However, two of these CpGs (cg11187204, cg10139436) also resided in 
intergenic regions that are either CpG-poor or sparsely represented on the 450k 
array, which would have precluded their identification using regional approaches. 
In our examination of 87 CpGs that have previously been associated with 
GDM status (9, 11, 12), only four were found to be differentially methylated in the 
same direction in the current meta-analysis, based on an uncorrected P < 0.05. 
Since these previous studies were similarly conducted in predominately 
European populations, differences in race or ethnicity are likely not driving these 
discrepancies. However, some of the prior findings may be false positives due to 
small samples sizes; insufficient control for multiple testing; or a lack of 
adjustment for important confounding factors, such as maternal BMI. Other 
potential explanations for the lack of replication include differences in exclusion 
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criteria and the fact that these previous studies stratified by fetal sex (9) or GDM 
treatment type (11, 12), which was not feasible for the current meta-analysis. 
Importantly, the seven cohorts participating in the current meta-analysis 
represent eight countries and multiple time periods. Since the criteria used to 
classify GDM differ by country and have changed across time, the severity of 
disease among GDM cases, and the proportion of controls with undiagnosed 
GDM or hyperglycemia, may have varied between cohorts. Nevertheless, we did 
not observe evidence of heterogeneity for the majority of meta-analysis results. 
Furthermore, results were generally similar across a series of sensitivity 
analyses, which stratified cohorts based on geographic location, time, and the 
criteria used for GDM classification. It is therefore possible that there may be a 
linear relationship between maternal glucose levels and cord blood DNA 
methylation. However, while there is some evidence for this (34), additional 
studies are needed to determine if maternal glucose is the main mechanism 
through which GDM alters DNA methylation and, if so, whether or not there is a 
clear threshold below which maternal glucose does not alter cord blood 
methylation. 
The current study had many notable strengths. By meta-analyzing results 
from multiple cohorts, we were able to increase the statistical power of the study 
and adjust for a large number of potential confounders, including estimated cell 
fractions. We also used stringent adjustments for multiple testing to reduce the 
chance of identifying false positives. Another strength of the study was the 
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evaluation of DMRs (using two different approaches) in addition to individual 
CpGs.  
However, our meta-analyses also had limitations. First, there may have 
been an overall underestimation of GDM cases, since GDM cases from several 
cohorts were diagnosed based on a selective approach. This may have resulted 
in some participants being misclassified as controls, which would have biased 
results toward the null. Another important consideration is that regression models 
were adjusted for maternal BMI, because it is a risk factor for GDM (35) and may 
impact cord blood DNA methylation (36). However, this may have also biased 
results toward the null, since GDM cases from several cohorts were diagnosed 
selectively based on traditional risk factors, including obesity. Importantly, women 
with GDM may have utilized different strategies to manage their disease. 
However, this information was not available for all cohorts, and the number of 
GDM cases adhering to particular management strategies or treatments was 
very small for most cohorts, so these differing subsets of GDM cases could not 
be evaluated separately. We also could not evaluate potential differences by fetal 
sex due to the small number of GDM cases per cohort. Additionally, since the 
gestational age at OGTT was not available for all participants, we were unable to 
adjust for this covariate. Another potential limitation was our focus on cord blood 
DNA methylation, which may not reflect methylation patterns in other tissues. 
However, cord blood DNA methylation has been associated with several 
outcomes that have been associated with in utero exposure to GDM, such as 
early childhood weight and adiposity (37) and ASD (38). While we excluded 
  22 
CpGs that overlapped SNPs and also CpG probes with SNPs at the single base 
pair extension (27), we cannot rule out the possibility that some of the 
differentially methylated CpGs and regions identified in this meta-analysis may 
be driven by genetic, rather than epigenetic, differences between GDM cases 
and controls, which merits future investigation. Finally, since the majority of 
individuals in the seven participating cohorts were of European ancestry, results 
from the current meta-analysis may not be generalizable to other populations. 
 
Conclusions: 
In a meta-analysis of integrated EWAS results from seven pregnancy 
cohorts, comprising data from 3,677 mother-newborn pairs, GDM was associated 
with lower cord blood methylation levels within the promoter region of OR2L13 
and the gene body of CYP2E1. Given that reduced methylation in the OR2L13 
promoter has previously been associated with both GDM status and ASD, its 
potential role in mediating this relationship should be evaluated in future studies. 
Additionally, since CYP2E1 is upregulated in peripheral blood from individuals 
with type 1 and type 2 diabetes, the impact of reduced methylation within this 
gene among GDM-exposed newborns on subsequent health merits future 
investigation. Finally, the inability to replicate many results from previous studies 
of GDM exposure and cord blood DNA methylation highlights the importance of 
conducting EWAS meta-analyses, using data from multiple cohorts. 
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Table 1. Characteristics of Participating Cohorts* 
Cohort Location Participant 
Enrollment 
Years 
GDM Screening Approach GDM 
Classification 
Criteria and 
Source of 
Information 
Number 
of GDM 
Cases 
Number 
of 
Controls 
ALSPAC United Kingdom 1991-1992 Selective Physician-
diagnosed 
GDM (Medical 
Records) 
22 867 
GOYA Denmark 1996-2002 Selective Physician-
diagnosed 
GDM based on 
a 1-Step 75 g 
OGTT 
(Medical 
Records) + 
Self-Report 
28 404 
Healthy Start United States 2009-2014 Universal Physician-
diagnosed 
GDM based on 
a 2-Step 100 g 
OGTT, 
Carpenter and 
Coustan 
Criteria 
(Medical 
Records) 
32 534 
INMA Spain 2004-2007 Selective 2-Step 100 g 
OGTT, 
Carpenter and 
Coustan 
Criteria 
(Medical 
Records) 
12 144 
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PREDO Finland 2006-2010 Universal 1-Step 75 g 
OGTT, 
IADPSG 
Criteria 
(Medical 
Records) 
180 600 
RHEA/ENVIRONAGE/Piccolipiù 
(Pooled) 
Greece/Belgium/Italy 2007-
2008/2010-
/2011-2015 
Universal/Universal/Universal 2-Step 100 g 
OGTT, 
Carpenter and 
Coustan 
Criteria 
(Medical 
Records)/2-
Step 100 g 
OGTT, 
Carpenter and 
Coustan 
Criteria 
(Medical 
Records)/Self-
Report 
20 352 
Project Viva United States 1999-2002 Universal 2-Step 100 g 
OGTT, 
Carpenter and 
Coustan 
Criteria 
(Medical 
Records) 
23 459 
 
Abbreviations used: GDM, gestational diabetes; IADPSG, International Association of the Diabetes and Pregnancy Study Groups; OGTT, oral 
glucose tolerance test 
 
*Additional details on GDM classification and other characteristics of each cohort are included in the “Cohort-Specific Methods” section of the 
Supplementary Data 
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Table 2. CpGs with a PFDR<0.10 in the Meta-Analysis of Maternal GDM Exposure* 
 
CpG Genomic Position 
%Methylation 
Difference (95%CI)† 
Direction 
by 
Cohort‡ 
Raw P-
Value 
FDR-
Corrected 
P-Value 
Heterogeneity 
P-Value§ 
I2 
Relation 
to CpG 
Island|| 
Target 
Gene¶ 
cg00812770 chr1:1073510 0.8% (0.5%, 1.1%) +-+++++ 1.7 x 10-7 0.06 0.55 0.0 
South 
Shore 
LINC01342 
cg11723077 chr6:158508188 -1.0% (-1.4%, -0.6%) -+----- 1.3 x 10-6 0.09 0.13 38.7 
South 
Shore SYNJ2 
cg22791932 chr16:88537374 0.8% (0.4%, 1.1%) +++-+++ 1.2 x 10-6 0.09 0.74 0.0 Island 
ZFPM1 
cg17588003 chr17:5138696 -1.4% (-2.0%, -0.8%) +------ 1.4 x 10-6 0.09 0.67 0.0 
Open 
Sea 
C17orf87 
cg11187204 chr17:36480526 -1.6% (-2.1%, -1.0%) ++----- 5.2 x 10-8 0.09 0.57 0.0 
Open 
Sea 
N/A 
cg10139436 chr19:30219558 -0.4% (-0.5%, -0.2%) ++----- 1.3 x 10-6 0.09 0.36 9.7 
South 
Shelf 
N/A 
 
*Results are from inverse variance-weighted fixed effects meta-analyses, conducted using METAL. Each cohort independently ran robust linear 
regression models, adjusting for newborn’s sex, maternal age (in years), maternal body mass index (early pregnancy or pre-pregnancy), maternal 
smoking status during pregnancy, maternal education, maternal genetic ancestry (if available) or maternal race/ethnicity, and estimated 
proportions of B cells, CD8+ T cells, CD4+ T cells, granulocytes, natural killer cells, monocytes, and nucleated red blood cells in cord blood. 
 
†%Difference in newborn DNA methylation and 95% confidence interval, comparing the gestational diabetes case group to the control group 
 
‡Direction of association between gestational diabetes and methylation at the locus of interest by cohort, ordered as follows: ALSPAC, GOYA, 
Healthy Start, INMA, PREDO, RHEA/ENVIRONAGE/Piccolipiù, Project Viva 
 
§The heterogeneity p-value and I2 were calculated by METAL using Cochran’s Q-test for heterogeneity. 
 
||Relationship to CpG islands from the UCSC database, annotated using the Illumina 450k manifest (28) 
 
¶Target gene name(s) from the UCSC database, annotated using the Illumina 450k manifest (28) 
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Table 3. Differentially Methylated Regions Identified By Both Comb-p and DMRcate* 
 
DMR 450k CpGs Direction 
of 
association  
Nearby Genes Regulatory Feature 
Group/Gene Group/Relation to 
Island 
Comb-p (500 and 1,000 bp 
window) 
    
chr1:248100345-248100614 cg00785941, 
cg03748376, 
cg04028570, 
cg08260406, 
cg08944170, 
cg20434529, 
cg20507276 
- OR2L13,CLK3P2 Promoter associated/1st 
Exon:5’UTR or TSS200/Island or 
North Shore 
chr10:135342218-135342413 cg10862468, 
cg25330361 
- CYP2E1 NA/Body/Island 
DMRcate (500 bp window)     
chr1:248100407-248100614 cg00785941, 
cg03748376, 
cg04028570, 
cg08260406, 
cg08944170, 
cg20507276 
- OR2L13 Promoter Associated/1st 
Exon/5’UTR/Island 
DMRcate (1,000 bp window)     
chr10:135341870-135342620 cg00321709, 
cg10862468, 
cg19469447, 
cg23400446, 
cg24530264, 
cg25330361 
- CYP2E1 Unclassified/Body/Island 
 
Abbreviations Used: bp, base pairs 
 
*Differentially methylated regions were identified from meta-analysis results for individual CpGs, which used results from robust linear regression 
models that were adjusted for newborn’s sex, maternal age (in years), maternal body mass index (pre-pregnancy or early pregnancy), maternal 
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education, maternal smoking status during pregnancy (ever vs. never), maternal genetic ancestry (if available) or maternal race/ethnicity, and 
estimated cord blood cell fractions. 
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Figure 1. Manhattan plot summarizing results for meta-analyses of the 
associations between maternal gestational diabetes mellitus and cord blood DNA 
methylation. Meta-analyses were run using METAL on results from robust linear 
regression models, which adjusted for newborn’s sex, maternal age, maternal 
education, maternal body mass index (pre-pregnancy or in early pregnancy), 
maternal smoking status during pregnancy (ever versus never), maternal genetic 
ancestry (if available) or maternal race/ethnicity, and estimated cord blood cell 
fractions. Blue and red lines indicate log10(p-values) that are equivalent to a PFDR 
of 0.10 and a PFDR of 0.05, respectively. 
